Company intelligence / Profile preview

Snyder Therapeutics

Baltimore, Maryland, USA

Ownership: Private
Development stage: Other

Overview

Snyder Therapeutics is a Baltimore-based biotechnology company founded by Dr. Solomon Snyder, a renowned neuroscientist from Johns Hopkins University. The company is dedicated to developing novel small molecule therapeutics that target the D-serine metabolic pathway to treat neurological and psychiatric disorders. Its lead research focus involves the development of serine racemase (SR) inhibitors, which aim to reduce excessive D-serine levels and prevent NMDA receptor-mediated excitotoxicity in conditions such as stroke and Alzheimer's disease. As a spin-out from Johns Hopkins, the company leverages decades of pioneering research into neurotransmitter systems and brain chemistry.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Snyder Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Snyder Therapeutics.

Explore the full profile